Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Adimab has initiated three new independent research collaborations with Eli Lilly, Genentech and Human Genome Sciences (HGS).
Subscribe to our email newsletter
In addition to the three new collaborations, Adimab has also reached a technical milestone in its ongoing collaboration with Novartis, which was initiated in June of 2010.
Under collaboration with Eli Lilly, Adimab will use its proprietary discovery platform to identify fully human antibodies against two targets selected by Lilly.
Adimab and Genentech, a member of the Roche Group, have initiated a research program whereby Adimab will use its proprietary yeast-based antibody discovery platform to identify fully human antibodies against two targets selected by Genentech.
Under the terms of the agreement, Genentech has rights to commercialize antibodies generated from the collaboration.
Adimab will receive upfront payments, preclinical milestones and licensing fees. In addition, Adimab is eligible to receive clinical development milestones and royalties on therapeutic and diagnostic product sales.
Adimab and HGS have initiated a research program whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against one target selected by HGS.
The agreement gives HGS the option to commercialize antibodies generated from the collaboration.
Adimab Business Development senior director said by incorporating target biology into the selection process they are able to generate very high quality leads in a short timeframe.